EMAIL THIS PAGE TO A FRIEND

Epilepsy research

Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.


PMID 12458024

Abstract

Multiple studies suggest that phenytoin concentrations increase with CBZ co-medication. This study evaluated the hypothesis that CBZ and/or its major metabolite (CBZE) inhibit CYP2C19-mediated phenytoin metabolism using human liver microsomes and cDNA-expressed CYP2C19. Oxcarbazepine (OXC), and its 10-monohydroxy metabolite (MHD) were also evaluated. CBZ and MHD inhibited CYP2C19-mediated phenytoin metabolism at therapeutic concentrations. Thus, administration of CBZ and OXC with CYP2C19 substrates with narrow therapeutic ranges should be done cautiously.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

UC126
4-Hydroxymephenytoin
C12H14N2O3
H146
4-Hydroxymephenytoin, ≥98% (HPLC)
C12H14N2O3